AR051296A1 - Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona - Google Patents
Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-onaInfo
- Publication number
- AR051296A1 AR051296A1 ARP050103934A ARP050103934A AR051296A1 AR 051296 A1 AR051296 A1 AR 051296A1 AR P050103934 A ARP050103934 A AR P050103934A AR P050103934 A ARP050103934 A AR P050103934A AR 051296 A1 AR051296 A1 AR 051296A1
- Authority
- AR
- Argentina
- Prior art keywords
- azepino
- tetrahydro
- fluoro
- phenyl
- methyl
- Prior art date
Links
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 title 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 229910019142 PO4 Inorganic materials 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61245904P | 2004-09-22 | 2004-09-22 | |
| US67929605P | 2005-05-09 | 2005-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051296A1 true AR051296A1 (es) | 2007-01-03 |
Family
ID=35526956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103934A AR051296A1 (es) | 2004-09-22 | 2005-09-20 | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7268126B2 (https=) |
| EP (1) | EP1799685B1 (https=) |
| JP (1) | JP2008513436A (https=) |
| KR (1) | KR100853601B1 (https=) |
| AR (1) | AR051296A1 (https=) |
| AT (1) | ATE551345T1 (https=) |
| AU (1) | AU2005286191B2 (https=) |
| BR (1) | BRPI0516766A (https=) |
| CA (1) | CA2581025C (https=) |
| ES (1) | ES2382950T3 (https=) |
| IL (1) | IL181463A (https=) |
| MX (1) | MX2007002461A (https=) |
| NO (1) | NO337938B1 (https=) |
| NZ (1) | NZ554659A (https=) |
| RU (1) | RU2355691C2 (https=) |
| TW (1) | TWI365188B (https=) |
| WO (1) | WO2006033007A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05010563A (es) * | 2003-03-31 | 2005-11-23 | Pfizer | Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas. |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| CA2615374A1 (en) * | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| JP2010502730A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | 癌の治療法 |
| CA2662337A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
| WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| KR20100102607A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 자궁암 및 난소암을 치료하는 방법 |
| CA2708157A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| PH12012500928A1 (en) | 2009-11-09 | 2012-11-26 | Allergan Inc | Compositions and methods for stimulating hair growth |
| EP2534153B2 (en) | 2010-02-12 | 2024-05-22 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| JP2013526514A (ja) | 2010-05-10 | 2013-06-24 | ラディカル・セラピューティックス・インコーポレイテッド | リポ酸およびニトロキシド誘導体およびその使用 |
| CN109602691A (zh) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| TWI721947B (zh) * | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| KR102803917B1 (ko) | 2014-08-22 | 2025-05-07 | 파르마＆ 슈바이츠 게엠베하 | 루카파립의 고 용량 강도 정제 |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10875870B2 (en) | 2017-01-24 | 2020-12-29 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| US11161865B2 (en) | 2017-05-24 | 2021-11-02 | The Trustees Of The University Of Pennsylvania | Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy |
| JP2021501771A (ja) * | 2017-11-03 | 2021-01-21 | サンド・アクチエンゲゼルシヤフト | 三環系ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤の結晶性塩 |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021156140A1 (en) | 2020-02-03 | 2021-08-12 | Sandoz Ag | Polymorph of rucaparib mesylate |
| EP4143182B1 (en) | 2020-04-28 | 2024-12-11 | Rhizen Pharmaceuticals AG | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| EP4182318B1 (en) | 2020-07-14 | 2025-08-27 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib salts |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| IL307339A (en) | 2021-04-08 | 2023-11-01 | Rhizen Pharmaceuticals Ag | Poly(ADP-ribose) polymerase inhibitors |
| WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
| KR20260030809A (ko) | 2023-06-21 | 2026-03-06 | 테트라곤 바이오사이언시스 엘티디 | Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US649554A (en) * | 1899-04-08 | 1900-05-15 | Ferdinand Schwedtmann | Electric switch. |
| GB8806449D0 (en) * | 1988-03-18 | 1988-04-20 | Janssen Pharmaceutica Nv | Antiviral hexahydroimiazo(1 4)benzodiazepin-2-ones |
| OA11749A (en) * | 1999-01-11 | 2005-07-19 | Agouron Pharma | Tricyclic inhibitors of poly(adp-ribose)polymerases. |
| MXPA05010563A (es) * | 2003-03-31 | 2005-11-23 | Pfizer | Sales de los inhibidores triciclicos de las poli(adp-ribosa) polimerasas. |
| SI1660095T1 (sl) * | 2003-07-25 | 2010-05-31 | Cancer Rec Tech Ltd | Triciklični parp inhibitorji |
-
2005
- 2005-09-12 EP EP05799991A patent/EP1799685B1/en not_active Expired - Lifetime
- 2005-09-12 WO PCT/IB2005/002941 patent/WO2006033007A2/en not_active Ceased
- 2005-09-12 AU AU2005286191A patent/AU2005286191B2/en not_active Ceased
- 2005-09-12 NZ NZ554659A patent/NZ554659A/en not_active IP Right Cessation
- 2005-09-12 RU RU2007110026/04A patent/RU2355691C2/ru active
- 2005-09-12 AT AT05799991T patent/ATE551345T1/de active
- 2005-09-12 MX MX2007002461A patent/MX2007002461A/es active IP Right Grant
- 2005-09-12 ES ES05799991T patent/ES2382950T3/es not_active Expired - Lifetime
- 2005-09-12 JP JP2007531869A patent/JP2008513436A/ja active Pending
- 2005-09-12 BR BRPI0516766-3A patent/BRPI0516766A/pt not_active Application Discontinuation
- 2005-09-12 KR KR1020077006422A patent/KR100853601B1/ko not_active Expired - Fee Related
- 2005-09-12 CA CA2581025A patent/CA2581025C/en not_active Expired - Lifetime
- 2005-09-20 AR ARP050103934A patent/AR051296A1/es unknown
- 2005-09-21 TW TW094132634A patent/TWI365188B/zh not_active IP Right Cessation
- 2005-09-21 US US11/233,835 patent/US7268126B2/en not_active Expired - Lifetime
-
2007
- 2007-02-16 NO NO20070920A patent/NO337938B1/no unknown
- 2007-02-20 IL IL181463A patent/IL181463A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ATE551345T1 (de) | 2012-04-15 |
| EP1799685B1 (en) | 2012-03-28 |
| NO20070920L (no) | 2007-03-15 |
| IL181463A0 (en) | 2007-07-04 |
| HK1116483A1 (en) | 2008-12-24 |
| NZ554659A (en) | 2010-08-27 |
| KR20070089121A (ko) | 2007-08-30 |
| IL181463A (en) | 2012-02-29 |
| ES2382950T3 (es) | 2012-06-14 |
| CA2581025A1 (en) | 2006-03-30 |
| EP1799685A2 (en) | 2007-06-27 |
| US7268126B2 (en) | 2007-09-11 |
| AU2005286191A1 (en) | 2006-03-30 |
| NO337938B1 (no) | 2016-07-11 |
| KR100853601B1 (ko) | 2008-08-22 |
| AU2005286191B2 (en) | 2011-11-17 |
| JP2008513436A (ja) | 2008-05-01 |
| CA2581025C (en) | 2011-06-07 |
| RU2007110026A (ru) | 2008-10-27 |
| TW200613305A (en) | 2006-05-01 |
| RU2355691C2 (ru) | 2009-05-20 |
| TWI365188B (en) | 2012-06-01 |
| MX2007002461A (es) | 2008-03-13 |
| BRPI0516766A (pt) | 2008-09-16 |
| WO2006033007A3 (en) | 2006-11-02 |
| US20060100198A1 (en) | 2006-05-11 |
| WO2006033007A2 (en) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051296A1 (es) | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona | |
| MX343383B (es) | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona. | |
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| BRPI0917119A2 (pt) | composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação. | |
| CL2007002669A1 (es) | Compuestos derivados de benzoxazol-2,7-disustituido y oxazol[5,4-c]-piridina; proceso de fabricacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por las cinasas jack2 y/o jack3 tal como cancer. | |
| WO2008003007A3 (en) | Compositions and methods for treating parasitic infections | |
| CL2009000954A1 (es) | Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras. | |
| PL2526934T4 (pl) | Inhibitory kinazy tyrozynowej Brutona | |
| CL2007002708A1 (es) | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. | |
| EA201001256A1 (ru) | Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств | |
| WO2010068483A3 (en) | Mlk inhibitors and methods of use | |
| NZ591425A (en) | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | |
| WO2006076620A3 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
| WO2008027584A3 (en) | 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase | |
| DK1812440T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser | |
| AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
| CR8642A (es) | Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos | |
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| CL2008001818A1 (es) | Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras. | |
| NI200800175A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias. | |
| UY29766A1 (es) | Formas cristalinas delta y épsilon de mesilato de imatinib | |
| WO2007076161A3 (en) | Compounds with therapeutic activity | |
| WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
| CL2009001137A1 (es) | Compuestos derivados de cicloheptanocarboniloxi-1-azonia-biciclo[2.2.2]-octano, moduladores de receptores muscarinicos; composiciones farmaceuticas; proceso de preparacion de dicha composicion; y uso en el tratamiento de una enfermedad pulmonar obstructiva cronica. | |
| CL2007002195A1 (es) | Compuesto n-((1r,2s,5r)-5-(isopropil(metil)amino)-2-((s)-2-oxo-3-(6-(trifluorometil)quinazolin-4-ilamino)pirrolidin-1-il)ciclohexil)acetamida; forma cristalina del compuesto; composicion farmaceutica; y uso en el tratamiento de enfermedades tales com |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |